

NIH Conference on Cancer, Autoimmunity and Immunology
March 22-23, 2018
Masur Auditorium, NIH Campus

	March 22, 2018
8:00 AM – 8:05 AM	Welcome: Elad Sharon, NCI
8:05 AM – 8:15 AM	Anthony S. Fauci, NIAID: Opening Remarks
8:15 AM – 8:35 AM	Suzanne Topalian, Johns Hopkins University: Immune-related adverse events with PD-1 blockade: uncoupling antitumor immunity from autoimmunity
8:35 AM – 8:40 AM	Q&A for Dr. Topalian
8:40 AM – 8:50 AM	Break
8:50 AM – 10:20 AM	Autoimmune Endocrinopathies
	Monica Girotra, Memorial Sloan-Kettering Cancer Center: An Overview of Autoimmune-Related Endocrinopathies Associated with Cancer Immunotherapy
	Alexander Faje, Massachusetts General Hospital: Fortuitous Misfortune? Hypophysitis Associated with Immune Checkpoint Inhibitors
	Patrizio Caturegli, Johns Hopkins University: A Pathologist's View of Hypophysitis Secondary to Cancer Immunotherapy
	Kevan Herold, Yale University: Autoimmune diabetes following treatment with checkpoint inhibitors
	Panel: Maya Lodish, NICHD, and Jennifer Blau, NICHD (Moderators)
10:20 AM – 10:40 AM	Break
10:40 AM – 10:55 AM	NCI Director Comments - Ned Sharpless, NCI: Emerging Areas in Immunotherapy at the National Cancer Institute
10:55 AM – 11:10 AM	FDA OCE Comments - Marc Theoret, FDA: A Regulatory Perspective
11:10 AM – 12:25 PM	Rheumatological Syndromes
	Clifton Bingham, Johns Hopkins University: Rheumatologic Consequences of Checkpoint Inhibitors
	Ami Shah, Johns Hopkins University: Is Scleroderma Caused by an Immunologic Response to Cancer?
	Andy Mammen, NIAMS: Neuromuscular Complications of Checkpoint Inhibitors
	Panel: Steve Katz, NIAMS (Moderator)
12:25 PM-1:40 PM	Lunch
1:40 PM – 3:10 PM	Diversity Immune-Related Adverse Events Observed in the Clinic and Lessons from Lupus
	Nicole LeBoeuf, Dana-Farber Cancer Institute: Skin Toxicities from Immune-Checkpoint Inhibitors
	David Hafler, Yale University: Unleashing the Immune System in the Brain

	Michael Dougan, Harvard University: GI Toxicities of Checkpoint Blockade
	Ignacio Sanz, Emory University: B cells Responses in Cancer: Lessons from SLE
	Panel: Elad Sharon, NCI (Moderator)
3:10 PM – 3:30 PM	Break
3:30 PM – 4:45 PM	Cardiovascular Autoimmunity
	Andrew Lichtman, Harvard University: T cell checkpoints regulate inflammation in the heart and arteries
	Javid Moslehi, Vanderbilt University: Immune checkpoint-associated myocarditis: Defining a new clinical entity
	Laleh Amiri-Kordestani, FDA: Cardiovascular adverse events and immune checkpoint inhibitors: An FDA perspective
	Panel: Helen Chen, NCI (Moderator)
	March 23, 2018
8:00 AM – 8:25 AM	Immune-related Adverse Events and Advancing Understanding of the Immune System
	Jeff Bluestone, Parker Institute for Cancer Immunotherapy (PICI): Autoimmunity following cancer treatment, more questions than answers
8:25 AM – 10:10 AM	What's the Big Picture? Initiatives for approaching irAEs
	David Kozono, Dana-Farber Cancer Institute: Alliance-NCI immune-related adverse events biorepository
	Sean Khozin, FDA: From big data to smart data: unlocking the power of diverse data assets for signal detection
	Orit Rozenblatt-Rosen, Broad Institute: Dissecting the Tumor Ecosystem with Single Cell Genomics
	Fred Ramsdell, Parker Institute for Cancer Immunotherapy: Parker Institute Pilot Programs to understand the mechanisms of irAEs
	Kristina Howard, FDA: Immune-mediated adverse events in humanized mice receiving checkpoint inhibitors
	Panel: Samantha Bailey-Bucktrout, Parker Institute for Cancer Immunotherapy (Moderator)
10:10 AM – 10:30 AM	Break
10:30 AM – 12:15 PM	When the Medicine Provides the Ammunition
	Evan Lipson, Johns Hopkins University: Immunotherapy for solid organ transplant recipients with advanced cancer
	Hussein Tawbi, MD Anderson Cancer Center: Prospective evaluation of checkpoint inhibitors in cancer patients with autoimmune disorders
	Jacqueline S. Garcia, Dana-Farber Cancer Institute: Evaluation of checkpoint inhibitors in hematologic malignancies pre- and post-allogeneic transplantation
	Nirali Shah, NCI: Toxicities Associated with Adoptive Cell Transfer
	Yvette Kasamon, FDA: Complications of Allogeneic HSCT Associated with PD-1 Inhibitors

	Panel: Howard Streicher, NCI (Moderator)
12:15 PM – 1:30 PM	Lunch
1:30 PM – 2:45 PM	Analysis of Existing Samples from Immunotherapy-Treated Patients
	Emanuel Maverakis, University of California-Davis: T cell repertoire analysis: One size does not fit all
	Sacha Gnjatic, Icahn School of Medicine at Mount Sinai: High-dimensional immune monitoring and immune-related adverse events
	Kavita Dhodapkar, Emory University: B cells in autoimmunity following combination checkpoint blockade
	Panel: Ron Germain, NIAID (Moderator)
2:45 PM – 3:05 PM	Break
3:05 PM – 4:50 PM	Infectious Disease, Immunodeficiency, and Immunoregulation
	Niroshana Anandasabapathy, Weill Cornell Medical College:
	Dan Barber, NIAID: The PD1 Pathway in Mycobacterial Infections
	Jennifer Kanakry, NCI: Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases of Immunodeficiency, Immune Dysregulation, and Autoimmunity
	Ethan Shevach, NIAID: Mechanisms of Treg-mediated suppression
	John Harris, University of Massachusetts-Worcester: Translational research in vitiligo: Gaining insight into mechanisms of organ-specific autoimmunity
	Panel: Howard Young, NCI (Moderator)